No Data
Express News | Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment With ClonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 50% Higher
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shareholders are no doubt pleased to see that the share price has bounced 50% in the last month, although it is still struggling to make up recently
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Why Adaptive Biotechnologies Topped the Market Today